Lidocaina Kabi

Lidocaine, the active ingredient in Lidocaina Kabi, is a local anesthetic (amide) presented as a sterile solution for epidural, intramuscular and intravenous use. It provides reversible nerve block for minor surgical procedures and analgesia in adult patients.

GNH USA supplies Lidocaina Kabi as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lidocaina Kabi is a local anesthetic indicated for several procedural and analgesic pathways. - Minor surgical procedures: provides local anesthesia for incision and minor tissue manipulation. - Epidural analgesia: delivers regional pain relief during labor or postoperative periods. - Intravenous regional anesthesia (Bier block): produces rapid, reversible anesthesia of a limb for short surgical interventions.

Lidocaina Kabi may cause a range of adverse reactions.

Common Side Effects: - Transient numbness or tingling at the injection site. - Dizziness or light‑headedness. - Metallic taste in the mouth. - Mild hypotension. - Nausea or mild vomiting. - Localized swelling or erythema.

Serious or Rare Side Effects: - Seizures or convulsions. - Cardiac arrhythmias, including ventricular tachycardia. - Severe hypotension or cardiovascular collapse. - Allergic reactions such as urticaria, angioedema, or anaphylaxis. - Methemoglobinemia. - Respiratory depression.

Before using Lidocaina Kabi, consider the following safety measures. - Allergy assessment: confirm no known hypersensitivity to amide‑type local anesthetics. - Cardiac monitoring: observe patients with pre‑existing heart disease or conduction abnormalities. - Dose calculation: adjust dose based on patient weight, age, and comorbidities. - Concurrent medications: review for drugs that may increase lidocaine toxicity. - Injection technique: use proper aseptic technique to avoid infection. - Store at controlled room temperature: keep in original container, protect from light, do not freeze.

Lidocaina Kabi can interact with several medicines; awareness helps prevent toxicity.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine, procainamide): may increase systemic lidocaine levels. - Beta‑adrenergic blockers: can exacerbate bradycardia and hypotension. - Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise plasma concentrations.

Moderate Interactions (Monitor Closely): - Other local anesthetics: additive neuro‑ and cardiotoxic effects. - Diuretics (e.g., furosemide): may reduce plasma protein binding, increasing free lidocaine. - General anesthetics (e.g., propofol, volatile agents): may potentiate central nervous system depression.